Becton, Dickinson and Company (BDXB) |
| 48.16 0.66 (1.39%) 05-31 16:00 |
| Open: | 47.2 |
| High: | 48.82 |
| Low: | 47.65 |
| Volume: | 2,764,320 |
| Market Cap: | 13,692(M) |
| PE Ratio: | 7.6 |
| Exchange: | New York Stock Exchange |
| Industry: | Medical - Instruments & Supplies |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 197.46 |
| Resistance 1: | 169.06 |
| Pivot price: | 158.20 |
| Support 1: | 156.19 |
| Support 2: | 148.23 |
| 52w High: | 52.52 |
| 52w Low: | 45.85 |
Becton, Dickinson and Company (BD) is a leading global medical technology enterprise. It designs, produces, and distributes a comprehensive portfolio of medical supplies, devices, laboratory instruments, and diagnostic solutions. Its diverse customer base spans healthcare institutions, medical professionals, life science researchers, clinical laboratories, the pharmaceutical industry, and consumers worldwide. The BD Medical segment concentrates on medication management and patient care. This division delivers a broad spectrum of products, including advanced IV and catheter systems (e.g., peripheral, central, dialysis), vascular access tools, and a variety of syringes and needles for general injection, anesthesia, and diabetes care. It also provides comprehensive solutions for medication preparation and administration, such as infusion therapy systems, automated dispensing units, and inventory tracking software, along with specialized prefillable drug delivery systems. The BD Life Sciences segment is dedicated to diagnostics and research. It supplies essential products for specimen and blood collection, along with advanced diagnostic systems covering automated blood and tuberculosis culturing, molecular testing, microorganism identification, drug susceptibility analysis, and liquid-based cytology. Furthermore, this segment provides rapid diagnostic assays, microbiology automation tools, and plated media. For cellular research and specialized clinical diagnostics, it offers fluorescence-activated cell sorters and analyzers, antibodies, reagent kits, and solutions for single-cell gene expression, oncology, immunology, and transplantation monitoring. BD Interventional provides a comprehensive portfolio for surgical and specialized interventional procedures. This encompasses products for hernia and soft tissue repair, a variety of biological and bioresorbable grafts, and biosurgery solutions. The segment also offers tools for surgical infection prevention, surgical and laparoscopic instrumentation, products for peripheral vascular intervention, and essential urology and critical care items. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
| EPS | 5.720 |
| Book Value | 87.580 |
| PEG Ratio | 1.11 |
| Gross Profit | 37.998 |
| Profit Margin (%) | 5.12 |
| Operating Margin (%) | 14.74 |
| Return on Assets (ttm) | 4.4 |
| Return on Equity (ttm) | 6.7 |
Tue, 16 Jun 2026
Medical Robots Market Worth $41.7 Billion by 2031 | MarketsandMarkets - Moomoo
Wed, 05 Feb 2025
BD Announces Intent to Separate Biosciences and Diagnostic Solutions Business to Enhance Focus, Drive Growth and Unlock Value - Becton Dickinson
Mon, 18 Apr 2022
April 18, 2022 - 8-K: Current report filing - Becton Dickinson
Wed, 11 Aug 2021
August 11, 2021 - 8-K: Current report filing - Becton Dickinson
Sat, 01 Aug 2026
Sat, 01 Aug 2026
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |